Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04960579 · ClinicalTrials.gov registry record · Phase 1
P-BCMA-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With Multiple Myeloma
A Phase 1 study of Multiple Myeloma, sponsored by Poseida Therapeutics.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 275
- Enrollment target
- 20
- Study locations
NCT04960579 is a Phase 1 study of Multiple Myeloma that is actively recruiting participants, run by Poseida Therapeutics. The registered enrollment target is 275 participants, below the 546-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (50% lower). The trial reports 20 study locations across 15 states.
The verdict
NCT04960579, a Phase 1 study of Multiple Myeloma, is actively recruiting participants, sponsored by Poseida Therapeutics.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 275 participants
- Enrollment target
- 20
- Study locations
Study Summary
Phase 1 study comprised of open-label, dose escalation, multiple cohorts of P-BCMA-ALLO1 allogeneic T stem cell memory (Tscm) CAR-T cells in subjects with relapsed / refractory Multiple Myeloma (RRMM).
Conditions Studied
Interventions
- DRUG Rimiducid
- DRUG Methotrexate
- BIOLOGICAL P-BCMA-ALLO1 CAR-T cells
Study Locations (20)
California
- University of California San Diego - San Diego
- University of California San Francisco - San Francisco
Georgia
- Emory University - Atlanta
- Blood Marrow and Transplant Group of Georgia - Atlanta
Illinois
- City of Hope - Chicago
- Advocate Aurora Health - Park Ridge
New York
- Roswell Park Comprehensive Cancer Center - Buffalo
- Mount Sinai - New York
Ohio
- University of Cincinnati - Cincinnati
- Cleveland Clinic - Cleveland
Arizona
- City of Hope - Goodyear
Iowa
- University of Iowa - Iowa City
Kansas
- University of Kansas Medical Center - Kansas City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 275 participants |
| Start Date | 2022-05-05 |
| Est. Completion | 2042-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04960579
The ClinicalTrials.gov registry entry for NCT04960579 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 275 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 546-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (50% lower). The listed sponsor is Poseida Therapeutics, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Multiple Myeloma appearing as the primary indexed condition, and to 3 interventions - of which Rimiducid is the first listed.
NCT04960579 reports 20 study locations spanning 15 distinct geographic areas - top geographies include California, Georgia, Illinois.
Frequently Asked Questions
What is clinical trial NCT04960579 about?
NCT04960579 is a clinical study titled "P-BCMA-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With Multiple Myeloma". Phase 1 study comprised of open-label, dose escalation, multiple cohorts of P-BCMA-ALLO1 allogeneic T stem cell memory (Tscm) CAR-T cells in subjects with relapsed / refractory Multiple Myeloma (RRMM).
What is the current status of trial NCT04960579?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 275 participants. The study started on 2022-05-05. Estimated completion is 2042-03.
What conditions does trial NCT04960579 study?
This clinical trial studies the following conditions: Multiple Myeloma.
What interventions are being tested in trial NCT04960579?
The interventions under investigation include: Rimiducid (DRUG), Methotrexate (DRUG), P-BCMA-ALLO1 CAR-T cells (BIOLOGICAL).
Who is sponsoring clinical trial NCT04960579?
This trial is sponsored by Poseida Therapeutics, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04960579 being conducted?
This trial has 20 study locations across Arizona, California, Georgia, Illinois, Iowa. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple Myeloma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments
RECRUITING · Phase 1
-
TriPRIL CAR T Cells in Multiple Myeloma
RECRUITING · Phase 1
-
A Study to Assess Adverse Events and Change in Disease Activity of Oral ABBV-453 Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)
RECRUITING · Phase 1
-
AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Relapsed/Refractory Multiple Myeloma
RECRUITING · Phase 1
-
Study of Carfilzomib, Lenalidomide, Dexamethasone and Belantamab Mafodotin in Multiple Myeloma
RECRUITING · Phase 1
-
CRISPR Delivered Anti-BCMA Car-T Therapy for Relapsed or Refractory Multiple Myeloma
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.